1. Updated guidance on the management of COVID-19: From an american thoracic society/european respiratory society coordinated international task force (29 July 2020)
- Author
-
Enrico Storti, Abhijit Duggal, Marcus J. Schultz, Catherine L. Hough, Chin Kook Rhee, Ziqiang Zhang, Wim A. Wuyts, Steven R Holets, George A. Alba, Jordi Rello, May Lee, Xun Wang, Sanjay H. Chotirmall, Ganesh Raghu, Charles Delacruz, Kristina Crothers, Jerry A. Krishnan, Iñigo Ojanguren, Kyeongman Jeon, Ari Moskowitz, Abigail Chua, Hassan Chami, Janice M. Liebler, Gerry N. McElvaney, Carey C. Thomson, Antoni Torres, Yeon Wook Kim, Maximiliano Tamae-Kakazu, Takeshi Johkoh, Richard R. Watkins, Oriol Roca, Margaret M. Hayes, Chunxue Bai, Leo M. A. Heunks, John G. Laffey, Dawei Yang, Francesca J. Torriani, Mathias W. Pletz, Mirko Belliato, Sugeet Jagpal, Robert S. Rogers, Miriam Barrecheguren, Gustavo A. Cortes-Puentes, Anthony O'Regan, Pierre-Régis Burgel, Julio Ramirez, Kevin C. Wilson, Elisabeth Bendstrup, Richard A. Oeckler, Tao Xu, Carlos M. Luna, Leo C. Ginns, Jordi Riera, Charlie Strange, James D. Chalmers, Michael S. Niederman, and Rongchang Chen
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Consensus ,International Cooperation ,Advisory Committees ,Pneumonia, Viral ,MEDLINE ,Reviews ,Context (language use) ,Disease ,Betacoronavirus ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Interim ,Pulmonary Medicine ,medicine ,Humans ,030212 general & internal medicine ,CODIV-19 ,Intensive care medicine ,Pandemics ,Societies, Medical ,Depression (differential diagnoses) ,lcsh:RC705-779 ,SARS-CoV-2 ,business.industry ,COVID-19 ,lcsh:Diseases of the respiratory system ,United States ,Europe ,Clinical trial ,030228 respiratory system ,Anxiety ,medicine.symptom ,Coronavirus Infections ,business - Abstract
Background Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and facilitating future research. Methods An International Task Force was composed and agreement regarding courses of action was measured using the Convergence of Opinion on Recommendations and Evidence (CORE) process. 70% agreement was necessary to make a consensus suggestion. Results The Task Force made consensus suggestions to treat patients with acute COVID-19 pneumonia with remdesivir and dexamethasone but suggested against hydroxychloroquine except in the context of a clinical trial; these are revisions of prior suggestions resulting from the interim publication of several randomised trials. It also suggested that COVID-19 patients with a venous thromboembolic event be treated with therapeutic anticoagulant therapy for 3 months. The Task Force was unable to reach sufficient agreement to yield consensus suggestions for the post-hospital care of COVID-19 survivors. The Task Force fell one vote shy of suggesting routine screening for depression, anxiety and post-traumatic stress disorder. Conclusions The Task Force addressed questions related to pharmacotherapy in patients with COVID-19 and the post-hospital care of survivors, yielding several consensus suggestions. Management options for which there is insufficient agreement to formulate a suggestion represent research priorities., For patients with acute COVID-19 pneumonia who require oxygen support, the International Task Force made suggestions for remdesivir and dexamethasone, but against hydroxychloroquine. Post-discharge management of COVID-19 survivors is a research priority. https://bit.ly/32B96uI
- Published
- 2020
- Full Text
- View/download PDF